Its primary pharmacological characterization was published in European Journal of Endocrinology (PMID 9849822), where the authors identified it as the first growth-hormone-secretagogue receptor (GHSR-1a) agonist achieving GH-release selectivity comparable to GHRH in animal models
Patients who want a straightforward, nightly injection protocol and have goals like gradual fat loss, improved recovery, better sleep and vitality may consider Sermorelin
For patients seeing skin laxity alongside fat loss, this stack addresses both processes simultaneously
SKINCARE THAT KEEPS ITS PROMISES Wash your face with a gentle cleanser and wait 15-30 minutes
Unlike a malar rash, discoid rashes dont span the width of the face
Instead of mimicking ghrelin, it stimulates the GHRH pathway, telling your pituitary gland to secrete more growth hormone